Paradoxical effects of anti-TNF-α agents in inflammatory diseases

Expert Review of Clinical Immunology

Volumn 10, Issue 1, 2014, Pages 159-169

  Wendling, Daniel ^a   Prati, Clément ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

anti TNF agents; Crohns disease; paradoxical effect; psoriasis; sarcoidosis; TNF ; uveitis; vasculitis

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; CERTOLIZUMAB PEGOL; ETANERCEPT; GAMMA INTERFERON; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALOPECIA AREATA; BASAL CELL CARCINOMA; CELLULITIS; CROHN DISEASE; CUTANEOUS T CELL LYMPHOMA; DERMATOMYCOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DRUG EFFECT; DRUG ERUPTION; DRUG HYPERSENSITIVITY; ECZEMA; ENTERITIS; ERYTHEMA; GRANULOMA; GRANULOMA ANNULARE; GRANULOMATOSIS; HERPES ZOSTER; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; LICHEN (DISEASE); LOCALIZED SCLERODERMA; MELANOCYTIC NEVUS; MELANOMA; NONHUMAN; PARADOXICAL DRUG REACTION; PATIENT PREFERENCE; PEMPHIGUS; POLYMYOSITIS; PSORIASIS; RELAPSING POLYCHONDRITIS; REVIEW; SARCOIDOSIS; SEZARY SYNDROME; SKIN LUPUS ERYTHEMATOSUS; SPONDYLARTHRITIS; URTICARIA; UVEITIS; VASCULITIS; VITILIGO;

ANIMALS; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; PSORIASIS; SARCOIDOSIS; SPONDYLARTHROPATHIES; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84893146936     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.866038     Document Type: Review

References (65)

1. Pham T, Bachelez H, Berthelot JM et al. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine. 78(Suppl. 1), 15-185 (2011).
2. Bradley Jr. TNF-mediated inflammatory disease. J. Pathol. 214(2), 149-160 (2008).
3. Tracey D, Klareskog L, Sasso EH et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117(2), 244-279 (2008).
4. Biton J, Boissier MC, Bessis N. TNFa: activator or inhibitor of regulatory T cells? Joint Bone Spine 79(2), 119-123 (2012).
5. Benucci M, Saviola G, Manfredi M et al. Tumor necrosis factors blocking agents: analogies and differences. Acta Biomed. 83(1), 72-80 (2012).
6. Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract. Res. Clin. Rheumatol. 25(4), 549-567 (2011).
7. Park W, Hrycaj P, Jeka S et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab inpatients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis. 72(10), 1605-1612 (2013)
8. Wendling D, Balblanc JC, Briançon D et al. Onset or exacerbation of cutaneous psoriasis during TNF alpha antagonist therapy. Joint Bone Spine 75(3), 315-318 (2008).
9. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J. Dermatolog. Treat. 20(2), 100-108 (2009).
10. Harrison MJ, Dixon WG, Watson KD et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 68(2), 209-215 (2009).
11. Tillack C, Ehmann LM, Friedrich M et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-g-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut doi:10.1136/gutjnl-2012-302853 (2013) (Epub ahead of print).
12. Klein RQ, Spivack J, Choate KA. Psoriatic skin lesions induced by certolizumab pegol. Arch. Dermatol. 146, 1055-1056 (2010).
13. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 59(7), 996-1001 (2008).
14. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin. Arthritis Rheum. 40(3), 233-240 (2010).
15. Denadai R, Teixeira FV, Steinwurz F et al. Induction or exacerbation of psoriatic lesions during anti-TNF-a therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J. Crohns Colitis. 7(7), 517-524 (2013).
16. Seneschal J, Milpied B, Vergier B et al. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br. J. Dermatol. 161(5), 1081-1088 (2009).
17. Ma HL, Napierata L, Stedman N et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum. 62(2), 430-440 (2010).
18. Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin. Exp. Rheumatol. 30(5), 700-706 (2012).
19. Viguier M, Richette P, Bachelez H et al. Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders. Expert Rev. Clin. Immunol. 5(4), 421-431 (2009).
20. Flendrie M, Vissers WH, Creemers MC et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res. Ther. 7(3), R666-R676 (2005).
21. Hernández MV, Sanmartí R, Can?ete JD et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumour necrosis factor antagonists. Study based on the Spanish Registry of Adverse Events of Biological Therapies in Rheumatic Diseases. Arthritis Care Res (Hoboken) doi:10.1002/ acr.22096 (2013) (Epub ahead of print).
22. Puig L, Morales-Munera CE, Lopez-Ferrer A, Geli C. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology 225(1), 14-17 (2012).
23. Cordero-Coma M, Yilmaz T, Onal S. Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul. Immunol. Inflamm. 21(1), 19-27 (2013).
24. Rifkin LM, Birnbaum AD, Goldstein DA. TNF Inhibition for ophthalmic indications: current status and outlook. Bio. Drugs 27(4), 347-357 (2013).
25. Wendling D. Uveitis in seronegative arthritis. Curr. Rheumatol. Rep.14(5), 402-408 (2012).
26. Guignard S, Gossec L, Salliot C et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares inpatients with spondylarthropathy: a retrospective study. Ann. Rheum. Dis. 65(12), 1631-1634 (2006).
27. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 52(8), 2447-2451 (2005).
28. Sieper J, Koenig A, Baumgartner S et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann. Rheum. Dis. 69(1), 226-229 (2010).
29. Rudwaleit M, Rødevand E, Holck P et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann. Rheum. Dis. 68(5), 696-701 (2009).
30. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 56(10), 3248-3252 (2007).
31. Wendling D, Paccou J, Berthelot JM et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin. Arthritis Rheum. 41(3), 503-510 (2011).
32. Fouache D, Goe?b V, Massy-Guillemant N et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford) 48(7), 761-764 (2009).
33. Horai R, Caspi RR. Cytokines in autoimmune uveitis. J. Interferon. Cytokine Res. 31(10), 733-744 (2011).
34. Gaujoux-Viala C, Giampietro C, Gaujoux T et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J. Rheumatol. 39(2), 233-239 (2012)
35. Braun J, Baraliakos X, Listing J et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 57(4), 639-647 (2007).
36. Toussirot E ́, Houvenagel E ́, Goe?b V et al. Development of inflammatory bowel disease during anti-TNF-a therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine 79(5), 457-463 (2012).
37. Fernandez Salazar L, Barrio Andres J, Gonzalez Hernandez JM. Crohns disease diagnosis during adalimumab treatment. Scand. J. Gastroenterol. 48(2), 254-255 (2013).
38. Haraoui B, Krelenbaum M. Emergence of Crohns disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin. Arthritis Rheum. 39(3), 176-181 (2009).
39. Siakavellas SI, Bamias G. Role of the IL-23/ IL-17 axis in Crohns disease. Discov. Med. 14(77), 253-262 (2012).
40. Maneiro JR, Salgado E, Gomez-Reino JJ et al. Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review. Semin. Arthritis Rheum. 42(1), 89-103 (2012).
41. Toussirot E, Pertuiset E, Kantelip B, Wendling D. Sarcoidosis occurring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin. Exp. Rheumatol. 26(3), 471-475 (2008).
42. Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. Semin. Arthritis Rheum. 39(4), 313-319 (2010).
43. Vigne C, Tebib JG, Pacheco Y, Coury F. Sarcoidosis: an underestimated and potentially severe side effect of anti-TNF-alpha therapy. Joint Bone Spine 80(1), 104-107 (2013).
44. Daien CI, Monnier A, Claudepierre P et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: cases. Rheumatology (Oxford) 48(8), 883-886 (2009).
45. Fok KC, Ng WW, Henderson CJ, Connor SJ. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J. Crohns Colitis. 6(6), 708-712 (2012).
46. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. 36(3), 159-67 (2006).
47. Toussirot E, Berthelot JM, Pertuiset E et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. J. Rheumatol. 36(11), 2421-2427 (2009).
48. Deng A, Harvey V, Sina B et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch. Dermatol. 142(2), 198-202 (2006).
49. Wendling D, Biver-Dalle C, Vidon C et al. Lichen planus under anti TNF therapy for ankylosing spondylitis. Joint Bone Spine 80(2), 227-228 (2013).
50. Wendling D, Streit G, Lehuedé G et al. Cutaneous lymphocytic vasculitis during TNF-alpha antagonist therapy for polyarthritis. Joint Bone Spine 73(2), 215-216 (2006).
51. Mohan N, Edwards ET, Cupps TR et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J. Rheumatol. 31(10), 1955-1958 (2004).
52. Saint Marcoux B, De Bandt M; CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 73(6), 710-713 (2006).
53. Ramos-Casals M, Brito-Zerón P, Munoz S et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of cases. Medicine (Baltimore) 86(4), 242-251 (2007).
54. Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-a inhibitors. Mayo Clin. Proc. 87(8), 739-745 (2012).
55. Wendling D. Biologics in the treatment of primary inflammatory myositis. Joint Bone Spine 74(4), 316-318 (2007).
56. Ishikawa Y, Yukawa N, Ohmura K et al. Etanercept-induced anti-Jo-1-antibodypositive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin. Rheumatol. 29(5), 563-566 (2010).
57. Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-a agents. Autoimmun. Rev. 13(1), 15-19 (2013).
58. Agarwal A, Andrews JM. Systematic review: IBD-associated pyodermagangrenosum in the biologic era, the response to therapy. Aliment Pharmacol. Ther. 38(6), 563-572 (2013)
59. Jaimes-Lopez N, Molina V, Arroyave JE et al. Development of pyodermagangrenosum during therapy with infliximab. J. Dermatol. Case Rep. 3(2), 20-23 (2009)
60. Vandevyvere K, Luyten FP, Verschueren P et al. Pyodermagangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin. Rheumatol. 26(12), 2205-2206 (2007)
61. Aubin F, Carbonnel F, Wendling D. The complexity of adverse side-effects to biological agents. J. Crohns Colitis. 7(4), 257-262 (2013).
62. Wendling D, Dougados M, Berenbaum F et al. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J. Rheumatol. 39(12), 2327-2331 (2012).
63. Wendling D, Letho-Gyselinck H, Guillot X, Prati C. Psoriasis onset with tocilizumab treatment for rheumatoid arthritis. J. Rheumatol. 39(3), 657 (2012).
64. Wendling D, Dernis E, Prati C et al. Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect? J. Rheumatol. 38(10), 2284 (2011).
65. Perez-Alvarez R, Perez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Biologics-induced autoimmune diseases. Curr. Opin. Rheumatol. 25(1), 56-64 (2013).